Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, Naiyer A., Hellmann, Matthew D., Snyder, Alexandra, Kvistborg, Pia, Makarov, Vladimir, Havel, Jonathan J., Lee, William, Yuan, Jianda +16 more·2015·Science
DOI 10.1126/science.aaa1348

Cited by (1,051)

Items 301–400 of 1,051

  1. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets
    Natasha Rekhtman, Maria Catherine Pietanza, Matthew David Hellmann, Jarushka Naidoo, Arshi Arora, Helen H. Won, Darragh F. Halpenny, Hangjun Wang, Shaozhou Ken Tian, Anya M. Litvak et al. · 2016 · Clinical Cancer Research
  2. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
    Suzanne George, Diana Miao, George D. Demetri, Dennis O. Adeegbe, Scott J. Rodig, Sachet Ashok Shukla, Mikel Lipschitz, Ali Amin‐Mansour, Chandrajit P. Raut, Scott L. Carter et al. · 2017 · Immunity
  3. PD-L1 Expression in Lung Cancer
    Yu, Hui, Boyle, Theresa A., Zhou, Caicun, Rimm, David L., Hirsch, Fred R. · 2016 · Journal of Thoracic Oncology
  4. B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer
    Daniel P. Hollern, Nuo Xu, Aatish Thennavan, Cherise Ryan Glodowski, Susana García‐Recio, Kevin Raynard Mott, Xiaping He, Joseph P. Garay, Kelly Carey-Ewend, David L. Marron et al. · 2019 · Cell
  5. Effects of Co-occurring Genomic Alterations on Outcomes in Patients with <i>KRAS</i> -Mutant Non–Small Cell Lung Cancer
    Arbour, Kathryn C., Jordan, Emmett, Kim, Hyunjae Ryan, Dienstag, Jordan, Yu, Helena A., Sanchez-Vega, Francisco, Lito, Piro, Berger, Michael, Solit, David B., Hellmann, Matthew et al. · 2018 · Clinical Cancer Research
  6. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
    Dickran Gano Kazandjian, Daniel L. Suzman, Gideon Michael Blumenthal, Sirisha L. Mushti, Kun He, Meredith Libeg, Patricia Keegan, Richard Pazdur · 2016 · The Oncologist
  7. Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
    Martin Lauss, Marco Donia, Katja Harbst, Rikke Sick Andersen, Shamik Mitra, Frida Rosengren, Maryem Salim, Johan Vallon‐Christersson, Therese Törngren, Anders Kvist et al. · 2017 · Nature Communications
  8. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
    Rilan Bai, Zheng Lv, Dongsheng Xu, Jiuwei Cui · 2020 · Biomarker Research
  9. Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel
    Wang, Zhijie, Duan, Jianchun, Cai, Shangli, Han, Miao, Dong, Hua, Zhao, Jun, Zhu, Bo, Wang, Shuhang, Zhuo, Minglei, Sun, Jianguo et al. · 2019 · JAMA Oncology
  10. Targeting T Cell Co-receptors for Cancer Therapy
    Margaret K. Callahan, Michael Andrew Postow, Jedd D. Wolchok · 2016 · Immunity
  11. Immunotherapy and Prevention of Pancreatic Cancer
    Alexander H. Morrison, Katelyn T. Byrne, Robert H. Vonderheide · 2018 · Trends in cancer
  12. Noncoding RNAs in gastric cancer: implications for drug resistance
    Ling Wei, Jujie Sun, Nasha Zhang, Yan Zheng, Xingwu Wang, Liyan Lv, Jiandong Liu, Yeyang Xu, Yue Shen, Ming Yang · 2020 · Molecular Cancer
  13. Acquired resistance to immunotherapy and future challenges
    Nicholas P. Restifo, Mark John Smyth, Alexandra Snyder · 2016 · Nature reviews. Cancer
  14. Neoantigen landscape dynamics during human melanoma–T cell interactions
    Els M.E. Verdegaal, Noel F.C.C. de Miranda, Marten Visser, Tom J. Harryvan, Marit M. van Buuren, Rikke Sick Andersen, Sine Reker Hadrup, Caroline E. van der Minne, Remko Schotte, Hergen Spits et al. · 2016 · Nature
  15. Genomic correlates of response to immune checkpoint blockade
    Keenan, Tanya E., Burke, Kelly P., Van Allen, Eliezer M. · 2019 · Nature Medicine
  16. PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy
    Salmaninejad, Arash, Valilou, Saeed Farajzadeh, Shabgah, Arezoo Gowhari, Aslani, Saeed, Alimardani, Malihe, Pasdar, Alireza, Sahebkar, Amirhossein · 2019 · Journal of Cellular Physiology
  17. Photodynamic Therapy Mediated by Nontoxic Core–Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer
    Xiaopin Duan, Christina Chan, Nining Guo, Wenbo Han, Ralph R. Weichselbaum, Wenbin Lin · 2016 · Journal of the American Chemical Society
  18. Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient
    Alejandro Jiménez-Sánchez, Danish Memon, Stephane Pourpe, Harini Veeraraghavan, Yanyun Li, Hebert Alberto Vargas, Michael B. Gill, Kay J. Park, Oliver Zivanovic, Jason A. Konner et al. · 2017 · Cell
  19. Microsatellite instability status determined by next‐generation sequencing and compared with PD ‐L1 and tumor mutational burden in 11,348 patients
    Ari M. Vanderwalde, David B. Spetzler, Nianqing Xiao, Zoran Gatalica, John Lindsay Marshall · 2018 · Cancer Medicine
  20. Targeted deletion of PD-1 in myeloid cells induces antitumor immunity
    Strauss, Laura, Mahmoud, Mohamed A. A., Weaver, Jessica D., Tijaro-Ovalle, Natalia M., Christofides, Anthos, Wang, Qi, Pal, Rinku, Yuan, Min, Asara, John, Patsoukis, Nikolaos et al. · 2020 · Science Immunology
  21. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
    Fenghua Wang, Xiaoli Wei, Fenggong Wang, Nong Xu, Lin Shen, Guanghai Dai, Xianglin Yuan, Yawen Chen, S. Yang, Jiawei Shi et al. · 2019 · Annals of Oncology
  22. The Landscape of Targeted Therapies in TNBC
    Elena Vagia, Devalingam Mahalingam, Massimo Cristofanilli · 2020 · Cancers
  23. Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors
    Leko, Vid, Rosenberg, Steven A. · 2020 · Cancer Cell
  24. 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations
    Tran, Eric, Robbins, Paul F, Rosenberg, Steven A · 2017 · Nature Immunology
  25. Resistance Mechanisms to Anti-PD Cancer Immunotherapy
    Vesely, Matthew D., Zhang, Tianxiang, Chen, Lieping · 2022 · Annual Review of Immunology
  26. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors
    Yang Liu, Yinping Dong, Li Kong, Fang Shi, Hui Zhu, Jinming Yu · 2018 · Journal of Hematology & Oncology
  27. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
    Luisa Carbognin, Sara Pilotto, Michèle Milella, Vanja Vaccaro, Matteo Brunelli, Anna Caliò, Federica Cuppone, Isabella Sperduti, Diana Giannarelli, Marco Chilosi et al. · 2015 · PLoS ONE
  28. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires
    Erlend Strønen, Mireille Toebes, Sander Kelderman, Marit M. van Buuren, Weiwen Yang, Nienke van Rooij, Marco Donia, Maxi-Lu Böschen, Fridtjof Lund‐Johansen, Johanna Olweus et al. · 2016 · Science
  29. Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
    Naiyer A. Rizvi, Matthew David Hellmann, Julie Renee Brahmer, Rosalyn Anne Juergens, Hossein Borghaei, Scott N. Gettinger, Laura Q.M. Chow, David E. Gerber, Scott Andrew Laurie, Jonathan Wade Goldman et al. · 2016 · Journal of Clinical Oncology
  30. Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer
    Liu, Baolin, Hu, Xueda, Feng, Kaichao, Gao, Ranran, Xue, Zhiqiang, Zhang, Sujie, Zhang, Yuanyuan, Corse, Emily, Hu, Yi, Han, Weidong et al. · 2021 · Nature Cancer
  31. The host STING pathway at the interface of cancer and immunity
    Corrales, Leticia, McWhirter, Sarah M., Dubensky, Thomas W., Gajewski, Thomas F. · 2016 · Journal of Clinical Investigation
  32. The immunology of renal cell carcinoma
    Claudia Marcela Diaz-Montero, Brian I. Rini, James Harold Finke · 2020 · Nature Reviews Nephrology
  33. Immune-related gene expression profiling after PD-1 blockade in non–small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma
    Prat, Aleix, Navarro, Alejandro, Paré, Laia, Reguart, Noemí, Galván, Patricia, Pascual, Tomás, Martínez, Alex, Nuciforo, Paolo, Comerma, Laura, Alos, Llucia et al. · 2017 · Cancer Research
  34. Glioblastoma targeted therapy: updated approaches from recent biological insights
    Mehdi Touat, Ahmed Idbaïh, Marc Sanson, Keith Lloyd Ligon · 2017 · Annals of Oncology
  35. Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma
    Yanyan Lou, Lixia Diao, Edwin Roger Parra, Warren L. Denning, Limo Chen, You Hong Fan, Lauren A. Byers, Jing Wang, Vassiliki A. Papadimitrakopoulou, Carmen Behrens et al. · 2016 · Clinical Cancer Research
  36. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer
    Dong, Zhong-Yi, Zhang, Jia-Tao, Liu, Si-Yang, Su, Jian, Zhang, Chao, Xie, Zhi, Zhou, Qing, Tu, Hai-Yan, Xu, Chong-Rui, Yan, Li-Xu et al. · 2017 · OncoImmunology
  37. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types
    Feng Wang, Qi Zhao, Ying-Nan Wang, Ying Jin, Ming-Ming He, Zexian Liu, Rui‐Hua Xu · 2019 · JAMA Oncology
  38. Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma
    Sandra P. D’Angelo, Luca Melchiori, Melinda S. Merchant, Donna B. Bernstein, John W. Glod, Rosandra Natasha Kaplan, Stephan A. Grupp, William D. Tap, Karen Chagin, Gwendolyn K. Binder et al. · 2018 · Cancer Discovery
  39. Classifying the evolutionary and ecological features of neoplasms
    Carlo C. Maley, Athena Aktipis, Trevor A. Graham, Andrea Sottoriva, Amy M. Boddy, Michalina Janiszewska, Ariosto Siqueira Silva, Marco Gerlinger, Yinyin Yuan, Kenneth J. Pienta et al. · 2017 · Nature reviews. Cancer
  40. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
    Michele Maio, Arnaud Scherpereel, Luana Calabrò, Joachim G.J.V. Aerts, S. Cedrés, Alessandra Bearz, Kristiaan Nackaerts, Dean Anthony Fennell, Dariusz Mirosław Kowalski, Anne S. Tsao et al. · 2017 · The Lancet Oncology
  41. Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
    Qingyang Lei, Dan Wang, Kai Sun, Liping Wang, Yi Zhang · 2020 · Frontiers in Cell and Developmental Biology
  42. Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)
    Patrick J. Danaher, Sarah E. Warren, Rongze Olivia. Lu, Josue A. Samayoa, Amy H. Sullivan, Irena Pekker, Brett Wallden, Francesco Maria Marincola, Alessandra Cesano · 2018 · Journal for ImmunoTherapy of Cancer
  43. Current Landscape of Immunotherapy in Breast Cancer: A Review
    Adams, Sylvia, Gatti-Mays, Margaret E., Kalinsky, Kevin, Korde, Larissa A., Sharon, Elad, Amiri-Kordestani, Laleh, Bear, Harry, McArthur, Heather L., Frank, Elizabeth, Perlmutter, Jane et al. · 2019 · JAMA Oncology
  44. The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer
    H. Courtney Hodges, Jacob G. Kirkland, Gerald R. Crabtree · 2016 · Cold Spring Harbor Perspectives in Medicine
  45. New insights into the role of <scp>EMT</scp> in tumor immune escape
    Terry, Stéphane, Savagner, Pierre, Ortiz‐Cuaran, Sandra, Mahjoubi, Linda, Saintigny, Pierre, Thiery, Jean‐Paul, Chouaib, Salem · 2017 · Molecular Oncology
  46. Neutrophils dominate the immune cell composition in non-small cell lung cancer
    Julia Kargl, Stephanie Busch, Grace H. Y. Yang, Kyoung-Hee Kim, Mark L. Hanke, Heather E. Metz, Jesse J. Hubbard, Sylvia M. Lee, David K. Madtes, Martin W. McIntosh et al. · 2017 · Nature Communications
  47. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study
    Giuseppe Giaccone, Chul Kim, Jillian Thompson, Colleen McGuire, Bhaskar Kallakury, Joeffrey J. Chahine, Maria A. Manning, Robin Mogg, Wendy M. Blumenschein, Ming Tony Tan et al. · 2018 · The Lancet Oncology
  48. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
    Wei Ding, Betsy R LaPlant, Timothy G. Call, Sameer Ashok Parikh, Jose Francisco Leis, Rong Lucy He, Tait D. Shanafelt, Sutapa Sinha, Jennifer G. Le‐Rademacher, Andrew L. Feldman et al. · 2017 · Blood
  49. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance
    Maria Secrier, Xiaodun Li, Nadeera de Silva, Matthew Eldridge, Gianmarco Contino, Jan Bornschein, Shona MacRae, Nicola Grehan, Maria O’Donovan, Ahmad Miremadi et al. · 2016 · Nature Genetics
  50. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy
    Tiffany R. Hodges, Martina Ott, Joanne Xiu, Zoran Gatalica, Jeffrey J. Swensen, Shouhao Zhou, Jason T. Huse, John de Groot, Shulin Li, Willem W. Overwijk et al. · 2017 · Neuro-Oncology
  51. Tumor immune evasion arises through loss of TNF sensitivity
    Kearney, Conor J., Vervoort, Stephin J., Hogg, Simon J., Ramsbottom, Kelly M., Freeman, Andrew J., Lalaoui, Najoua, Pijpers, Lizzy, Michie, Jessica, Brown, Kristin K., Knight, Deborah A. et al. · 2018 · Science Immunology
  52. Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer
    Vanguri, Rami S., Luo, Jia, Aukerman, Andrew T., Egger, Jacklynn V., Fong, Christopher J., Horvat, Natally, Pagano, Andrew, Araujo-Filho, Jose de Arimateia Batista, Geneslaw, Luke, Rizvi, Hira et al. · 2022 · Nature Cancer
  53. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
    Xiangjiao Meng, Zhaoqin Huang, Feifei Teng, Ligang Xing, Jinming Yu · 2015 · Cancer Treatment Reviews
  54. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
    Michael B. Bernstein, Sunil Krishnan, James W. Hodge, Joe Yujiao Chang · 2016 · Nature Reviews Clinical Oncology
  55. TIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer
    de Mingo Pulido, Álvaro, Gardner, Alycia, Hiebler, Shandi, Soliman, Hatem, Rugo, Hope S., Krummel, Matthew F., Coussens, Lisa M., Ruffell, Brian · 2018 · Cancer Cell
  56. Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status
    Ricciuti, Biagio, Arbour, Kathryn C., Lin, Jessica J., Vajdi, Amir, Vokes, Natalie, Hong, Lingzhi, Zhang, Jianjun, Tolstorukov, Michael Y., Li, Yvonne Y., Spurr, Liam F. et al. · 2022 · Journal of Thoracic Oncology
  57. Mechanisms of Resistance to PD-1 and PD-L1 Blockade
    Theodore Scott Nowicki, Siwen Hu‐Lieskovan, Antoni Ribas · 2018 · The Cancer Journal
  58. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung Cancer
    Reinhard Büttner, John R. Gosney, Birgit Guldhammer Skov, Julien Adam, Noriko Motoi, Kenneth Joel Bloom, Manfred Dietel, John W. Longshore, Fernando López‐Ríos, Frederique Madeleine Penault-Llorca et al. · 2017 · Journal of Clinical Oncology
  59. Dose-Response Association of CD8 + Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
    Ellen L. Goode, Matthew Stephen Block, Kimberly R. Kalli, Robert Alan Vierkant, Wenqian Chen, Zachary C. Fogarty, Aleksandra Gentry‐Maharaj, Aleksandra D. Toloczko, Alexander Hein, Aliecia Bouligny et al. · 2017 · JAMA Oncology
  60. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer
    Voabil, Paula, de Bruijn, Marjolein, Roelofsen, Lisanne M., Hendriks, Sanne H., Brokamp, Simone, van den Braber, Marlous, Broeks, Annegien, Sanders, Joyce, Herzig, Petra, Zippelius, Alfred et al. · 2021 · Nature Medicine
  61. DNA sequencing technologies: 2006–2016
    Elaine R. Mardis · 2017 · Nature Protocols
  62. T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection
    Jonathan Trujillo, Randy F. Sweis, Riyue Bao, Jason J. Luke · 2018 · Cancer Immunology Research
  63. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions
    Liliang Xia, Yuanyong Liu, Ying Wang · 2019 · The Oncologist
  64. Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence
    Samuel Jacob Klempner, David A. Fabrizio, Shalmali Bane, Marcia L. Reinhart, Tim Peoples, Siraj Mahamed Ali, Ethan S. Sokol, Garrett Michael Frampton, Alexa Betzig Schrock, Rachel Anhorn et al. · 2019 · The Oncologist
  65. Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer
    Posch, Florian, Silina, Karina, Leibl, Sebastian, Mündlein, Axel, Moch, Holger, Siebenhüner, Alexander, Samaras, Panagiotis, Riedl, Jakob, Stotz, Michael, Szkandera, Joanna et al. · 2018 · OncoImmunology
  66. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial
    Wang, Jie, Lu, Shun, Yu, Xinmin, Hu, Yanping, Sun, Yuping, Wang, Zhijie, Zhao, Jun, Yu, Yan, Hu, Chunhong, Yang, Kunyu et al. · 2021 · JAMA Oncology
  67. Immunotherapy in ovarian cancer
    Kunle O. Odunsi · 2017 · Annals of Oncology
  68. Prospects of immune checkpoint modulators in the treatment of glioblastoma
    Matthias Preusser, Michael K. Lim, David A. Hafler, David A. Reardon, John Howard Sampson · 2015 · Nature Reviews Neurology
  69. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy
    Gerald Goh, Trent J. Walradt, Vladimir Markarov, Astrid Blom, Nadeem Riaz, Ryan Doumani, K. Stafstrom, Ata S. Moshiri, Lola Yelistratova, Jonathan L. Levinsohn et al. · 2015 · Oncotarget
  70. Tumor neoantigens: from basic research to clinical applications
    Tao Jiang, Tao Shi, Henghui Zhang, Jie Hu, Yuanlin Song, Jia Wei, Shengxiang Ren, Caicun Zhou · 2019 · Journal of Hematology & Oncology
  71. Cancer DNA vaccines: current preclinical and clinical developments and future perspectives
    Alessandra Lopes, Gaëlle Vandermeulen, Véronique Préat A · 2019 · Journal of Experimental & Clinical Cancer Research
  72. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer
    Sanja Stevanović, Anna Pasetto, Sarah R. Helman, Jared J. Gartner, Todd D. Prickett, Bryan Howie, Harlan S. Robins, Paul F. Robbins, Christopher Austin Klebanoff, Steven A. Rosenberg et al. · 2017 · Science
  73. Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis
    Otília Menyhárt, Balázs Győrffy · 2021 · Computational and Structural Biotechnology Journal
  74. UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma
    Yochai Wolf, Osnat Bartok, Sushant Patkar, Gitit Bar Eli, Sapir Cohen, Kevin Litchfield, Ronen Levy, Alejandro Jiménez-Sánchez, Sophie Trabish, Joo Sang Lee et al. · 2019 · Cell
  75. The Immunoscore: Colon Cancer and Beyond
    Helen K. Angell, Daniela Bruni, J. Carl Barrett, Ronald Herbst, Jérôme Galon · 2019 · Clinical Cancer Research
  76. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
    Janice M. Mehnert, Anshuman Panda, Judy Zhong, Kim Marie Hirshfield, Sherri Damare, Katherine Lane, Levi O. Sokol, Mark N. Stein, Lorna Rodriguez-Rodriquez, Howard L. Kaufman et al. · 2016 · Journal of Clinical Investigation
  77. Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy
    Anna E. Vilgelm, Ann J. Richmond · 2019 · Frontiers in Immunology
  78. Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
    Biagio Ricciuti, Xinan Wang, Joao V. Alessi, Hira A. Rizvi, Navin R. Mahadevan, Yvonne Y. Li, Andrew Polio, James R. Lindsay, Renato Umeton, Rileen Sinha et al. · 2022 · JAMA Oncology
  79. Combination immunotherapy: a road map
    Patrick Alexander Ott, Frank Stephen Hodi, Howard L. Kaufman, Jon M. Wigginton, Jedd D. Wolchok · 2017 · Journal for ImmunoTherapy of Cancer
  80. Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study
    Kuniko Sunami, Hitoshi Ichikawa, Takashi Kubo, Mamoru Kato, Yutaka Fujiwara, Akihiko Shimomura, Takafumi Koyama, Hiroki Kakishima, Mayuko Kitami, Hiromichi Matsushita et al. · 2019 · Cancer Science
  81. Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer
    Dong Ha Kim, HyeongRyul Kim, Yun Jung Choi, Seon Ye Kim, Jung-Eun Lee, Ki Jung Sung, Young Hoon Sung, Chan‐Gi Pack, Minkyo Jung, Buhm Han et al. · 2019 · Experimental & Molecular Medicine
  82. Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma
    Nicolás A. Giraldo, Étienne Becht, Yann Alexandre Vano, Florent Petitprez, Laetitia Lacroix, Pierre Validire, Rafael Sánchez-Salas, Alexandre Ingels, Stéphane Marie. Oudard, Audrey Moatti et al. · 2017 · Clinical Cancer Research
  83. Ovarian Cancer Immunotherapy and Personalized Medicine
    Susan M. Morand, Monika Devanaboyina, Hannah Staats, Laura Stanbery, John J. Nemunaitis · 2021 · International Journal of Molecular Sciences
  84. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes
    Cyrille J. Cohen, Jared J. Gartner, Miryam Horovitz‐Fried, Katerina Shamalov, Kasia Trebska-McGowan, Valery V. Bliskovsky, Maria R. Parkhurst, Chen Ankri, Todd D. Prickett, Jessica S. Crystal et al. · 2015 · Journal of Clinical Investigation
  85. A panoply of errors: polymerase proofreading domain mutations in cancer
    Emily Rayner, Inge C. van Gool, Claire Palles, Stephen E. Kearsey, Tjalling Bosse, Ian P.M. Tomlinson, David N. Church · 2016 · Nature reviews. Cancer
  86. Improving radiotherapy in cancer treatment: Promises and challenges
    Helen H.W. Chen, Macus Tien Kuo · 2017 · Oncotarget
  87. Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations
    Zishuo I. Hu, Jinru Shia, Zsofia Kinga Stadler, Anna M. Varghese, Marinela Capanu, Erin E. Salo‐Mullen, Maeve Aine Lowery, Luis Alberto Diaz, Diana L. Mandelker, Kenneth H. Yu et al. · 2018 · Clinical Cancer Research
  88. Mechanisms regulating T-cell infiltration and activity in solid tumors
    Lanitis, E., Dangaj, D., Irving, M., Coukos, G. · 2017 · Annals of Oncology
  89. Prospects for gene-engineered T cell immunotherapy for solid cancers
    Christopher Austin Klebanoff, Steven A. Rosenberg, Nicholas P. Restifo · 2016 · Nature Medicine
  90. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
    Katherine Hastings, Helena Alexandra Yu, Wen Wei, Francisco Sánchez-Vega, Michelle DeVeaux, Jungmin Choi, Hira A. Rizvi, Aaron Elliott Lisberg, Anna Truini, Christine Lydon et al. · 2019 · Annals of Oncology
  91. Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification
    Andrew M. Leader, John A. Grout, Barbara B. Maier, Barzin Y. Nabet, Matthew D. Park, Alexandra Tabachnikova, Christie Chang, Laura A. Walker, Alona Lansky, Jessica Le Bérichel et al. · 2021 · Cancer Cell
  92. Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer
    Ramaswamy Govindan, Aleksandra Szczęsna, Myung‐Ju Ahn, Claus-Peter Schneider, Pablo González Mella, Fabrice Barlési, Baohui Han, Doina Elena Ganea, Joachim von Pawel, Vladimir Ivanovich Vladimirov et al. · 2017 · Journal of Clinical Oncology
  93. Epigenetic Therapeutics: A New Weapon in the War Against Cancer
    Nita Ahuja, Anup R. Sharma, Stephen B. Baylin · 2016 · Annual Review of Medicine
  94. Prevalence and mutational determinants of high tumor mutation burden in breast cancer
    Romualdo Barroso‐Sousa, Esha Jain, Ofir Cohen, D. Kim, Jorge E. Buendia-Buendia, Eric P. Winer, NU Lin, Sara M. Tolaney, Nikhil Wagle · 2020 · Annals of Oncology
  95. Implications of the tumor immune microenvironment for staging and therapeutics
    Janis Marie Taube, Jérôme Galon, Lynette Marie Sholl, Scott J. Rodig, Tricia R. Cottrell, Nicolás A. Giraldo, Alexander Spyridon Baras, Sanjay S. Patel, Robert A. Anders, David L. Rimm et al. · 2017 · Modern Pathology
  96. Hyperprogressive disease: recognizing a novel pattern to improve patient management
    Stéphane Champiat, Roberto Ferrara, Christophe Massard, Benjamin Besse, Aurélien Marabelle, Jean‐Charles Soria, Charles Ferté · 2018 · Nature Reviews Clinical Oncology
  97. Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG Oncology Study
    Zamarin, Dmitriy, Burger, Robert A., Sill, Michael W., Powell, Daniel J., Lankes, Heather A., Feldman, Michael D., Zivanovic, Oliver, Gunderson, Camille, Ko, Emily, Mathews, Cara et al. · 2020 · Journal of Clinical Oncology
  98. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1
    Joohee Sul, Gideon Michael Blumenthal, Xiaoping Jiang, Kun He, Patricia Keegan, Richard Pazdur · 2016 · The Oncologist
  99. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma
    Chun Jye Lim, Yun Hua Lee, Lu Pan, Liyun Lai, Camillus Jian Hui Chua, Martin Wasser, Tony Kiat Hon Lim, Joe Poh-Sheng Yeong, Han Chong Toh, Ser Yee Lee et al. · 2018 · Gut
  100. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer
    Lin, Anqi, Zhang, Jian, Luo, Peng · 2020 · Frontiers in Immunology